Tuesday, August 31, 2021 4:30:10 PM
In the last year, one of the priorities of Foreign Minister Marcelo Ebrard has been the negotiation with the different pharmaceutical companies and governments of the world to achieve the arrival to the country of vaccines against Covid-19, a management that has even been praised by critics and most staunch opponents of Q4 and of the strategy headed by the Undersecretary of Health Hugo López-Gatell.
Now, and while the Delta variant causes a worsening of the pandemic in much of the world, Mexico included, Ebrard announced during his appearance before the Morena senators that the health authorities could authorize in a short time another 3 biologicals to join the campaign of vaccination.
"We are going to have, in the coming days, other types of authorizations for phase III in Mexico, such as Walvax, which is a Chinese messenger RNA vaccine; Inovio, which is a vaccine based on North American DNA; or Sanofi, which it is a vaccine of French origin, "said the head of Mexican diplomacy.
This announcement comes some after Cofepris approved the Sinopharm vaccine for emergency use, which will be the third Chinese vaccine that will begin to be applied in the country, as is already being done in 40 countries, including much of the Asian continent and Latin America. .
It will also be the ninth vaccine that residents of Mexico will be inoculated with, after the regulatory agency gave the go-ahead in the past to Pfizer, AstraZeneca, Cansino, Sputnik V, Sinovac, Covaxin, Janssen and Moderna vaccines.
In making the announcement, Ebrard said that this was part of the strategy to "have timely access to vaccines and accelerate vaccination in Mexico to try to contain and reduce the impact of the pandemic."
In addition, he said that negotiations with the Biden government will continue to open the land borders with the United States as soon as possible, something that the Chancellor himself recognized in recent days that will not be in the short term due to the increase in cases due to the Delta variant. although he said he was confident that it will be before the end of the year.
According to the latest official data, almost 84 million vaccines have been applied in Mexico since the start of the vaccination program in late December, and 3.4 million vaccines arrived this week alone, in shipments from Pifizer, Cansino and Moderna.
Around 33 million have already been immunized in Mexico against Covid-19, with Mexico City, Baja California and Baja California Sur being the states with the largest population vaccinated with the two doses.
https://www-lapoliticaonline-com-mx.translate.goog/nota/137951-la-4t-impulsa-la-autorizacion-de-3-nuevas-vacunas-contra-el-covid/?_x_tr_sl=es&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=ajax,nv,elem
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM